Krishna Institute of Medical Sciences Ltd Upgraded to Hold on Technical and Valuation Improvements

Technical Trend Upgrade Spurs Rating Change

The primary catalyst for the upgrade lies in the technical analysis domain, where KIMS’s technical grade has shifted from mildly bullish to bullish. Key momentum indicators reveal a mixed but improving picture. On a weekly basis, the MACD (Moving Average Convergence Divergence) is bullish, supported by a bullish KST (Know Sure Thing) and On-Balance Volume (OBV), while monthly indicators remain mildly bearish or neutral. The daily moving averages also confirm a bullish trend, reinforcing short-term positive momentum.

Bollinger Bands on both weekly and monthly charts show mild bullishness, suggesting that price volatility is stabilising with a positive bias. Meanwhile, the Dow Theory weekly signals are mildly bullish, although monthly trends show no clear direction. The Relative Strength Index (RSI) remains neutral on both weekly and monthly timeframes, indicating no immediate overbought or oversold conditions.

This technical improvement is significant given the stock’s recent price action, which saw a slight decline of 0.94% on the day to ₹746.55, with a 52-week high of ₹798.00 and a low of ₹575.55. Despite short-term volatility, the technical signals suggest a foundation for potential upward movement, justifying the upgrade to Hold.

Valuation Adjusted from Very Expensive to Expensive

Alongside technical improvements, the valuation grade for KIMS has been revised from very expensive to expensive. The company currently trades at a price-to-earnings (PE) ratio of 120.57, which remains high but is more palatable compared to its previous standing. The price-to-book value stands at 13.30, while enterprise value to EBIT and EBITDA ratios are 65.66 and 42.47 respectively, indicating a premium valuation relative to earnings and cash flow.

Return on capital employed (ROCE) is modest at 8.09%, and return on equity (ROE) is 11.03%, reflecting moderate profitability. The enterprise value to capital employed ratio of 5.31 suggests that the stock is trading at a discount compared to some peers, despite its expensive multiples. This relative valuation improvement supports the Hold rating, signalling that while the stock remains pricey, it is less stretched than before.

Comparatively, peers such as Aster DM Healthcare and Dr Lal Pathlabs maintain very expensive valuations, with PE ratios of 92.52 and 49.62 respectively, but KIMS’s elevated multiples reflect expectations of growth and sector positioning.

Financial Trend: Mixed Signals Amidst Profit Declines

Despite the upgrade, KIMS’s recent financial performance remains a concern. The company reported very negative results for Q4 FY25-26, with operating profit declining at an annual rate of 11.48% over the past five years. The last four consecutive quarters have seen negative earnings results, with profit before tax (PBT) falling by 41.3% to ₹56.00 crores and profit after tax (PAT) declining by 32.8% to ₹49.08 crores compared to the previous four-quarter average.

Operating profit to interest coverage ratio has deteriorated to a low of 3.03 times, although the average EBIT to interest ratio remains strong at 12.59, indicating the company’s ability to service debt is intact. High management efficiency is reflected in a robust ROCE of 17.88%, which contrasts with the latest quarter’s weaker profitability metrics.

Institutional holdings remain high at 47.07%, suggesting that informed investors maintain confidence in the company’s long-term prospects despite short-term setbacks. Market-beating returns over the last three years (139.04%) and one year (11.49%) further underscore the stock’s resilience relative to the BSE Sensex, which has returned 19.35% and -8.26% respectively over the same periods.

Long-Term Performance and Market Comparison

Krishna Institute of Medical Sciences has outperformed the broader market consistently over multiple time horizons. Year-to-date returns stand at 22.97%, significantly ahead of the Sensex’s -12.40%. Over three years, the stock has delivered a remarkable 139.04% return compared to the Sensex’s 19.35%. This outperformance highlights the company’s strong market positioning within the hospital and healthcare services sector.

However, the stock’s recent one-week performance was weaker, with a 2.76% decline versus the Sensex’s 1.79% fall, reflecting short-term volatility. The stock’s current price of ₹746.55 is close to its 52-week high of ₹798.00, indicating limited upside in the near term but a solid base for potential recovery.

Quality Assessment: Balanced Strengths and Weaknesses

The quality of Krishna Institute of Medical Sciences is reflected in its mixed financial and operational metrics. While recent quarterly results have been disappointing, the company’s management efficiency remains high, as evidenced by a ROCE of 17.88%. This suggests effective capital utilisation despite profit pressures.

Institutional investor confidence, with holdings at 47.07%, further supports the company’s quality credentials. However, the persistent decline in operating profit and negative quarterly earnings highlight ongoing challenges in sustaining growth and profitability. Investors should weigh these factors carefully when considering the stock’s medium-term outlook.

Conclusion: Hold Rating Reflects Cautious Optimism

The upgrade of Krishna Institute of Medical Sciences Ltd from Sell to Hold is driven primarily by improved technical indicators and a more reasonable valuation stance, despite continued financial headwinds. The stock’s strong long-term returns and institutional backing provide a foundation for cautious optimism, while recent profit declines and expensive multiples warrant prudence.

Investors should monitor upcoming quarterly results closely and consider the stock’s technical momentum alongside fundamental developments. The Hold rating suggests that while the stock is not currently a strong buy, it remains a viable option for investors seeking exposure to the hospital sector with a balanced risk-reward profile.

Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year Start at 33% Off →